A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
LAVIPHARM S.A. operates in the Drug Manufacturers - Specialty & Generic industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 57M | 57M | 52M |
| Net Income | 0 | - | - |
| EPS | $555.34 | $555.34 | $127.03 |
| Free Cash Flow | 5.0M | 5.0M | 308K |
| ROIC | 8.3% | 6.3% | 6.5% |
| Gross Margin | 47.4% | 47.4% | 46.3% |
| Debt/Equity | 0.00 | 0.39 | 0.45 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | 6.0M | 6.0M | 5.6M |
| Operating Margin | 10.5% | 10.5% | 10.8% |
| ROE | 0.0% | - | - |
| Shares Outstanding | 0M | - | - |
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Income Statement | |||
| Revenue | 52M | 57M | 57M |
| Gross Margin | 46.3% | 47.4% | 47.4% |
| R&D | -467K | -682K | -682K |
| SG&A | 19M | 22M | 22M |
| EBIT | 5.6M | 6.0M | 6.0M |
| Op. Margin | 10.8% | 10.5% | 10.5% |
| Net Income | N/A | N/A | 0 |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | 6.5% | 6.3% | 8.3% |
| ROE | N/A | N/A | 0.0% |
| ROA | N/A | N/A | 0.0% |
| Cash Flow | |||
| Op. Cash Flow | 308K | 5.0M | 5.0M |
| Free Cash Flow | 308K | 5.0M | 5.0M |
| Owner Earnings | -4.3M | 65K | 65K |
| CapEx | 0 | 0 | 0 |
| Maint. CapEx | 4.6M | 4.9M | 4.9M |
| Growth CapEx | N/A | N/A | 0 |
| D&A | 4.6M | 4.9M | 4.9M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A |
| Debt Repayment | 55M | 34M | 34M |
| Balance Sheet | |||
| Net Debt | 21M | 22M | 0 |
| Cash & Equiv. | N/A | N/A | N/A |
| Long-Term Debt | 12M | 11M | 11M |
| Debt/Equity | 0.45 | 0.39 | 0.00 |
| Interest Coverage | 2.3 | 2.6 | 2.6 |
| Equity | 46M | 57M | 57M |
| Total Assets | 125M | 136M | 136M |
| Total Liabilities | 78M | 78M | 78M |
| Intangibles | 48M | 54M | 54M |
| Retained Earnings | -35M | -26M | -26M |
| Working Capital | 11M | 6.3M | 6.3M |
| Current Assets | 50M | 49M | 49M |
| Current Liabilities | 39M | 42M | 42M |
| Per Share Data | |||
| EPS | 127.03 | 555.34 | 555.34 |
| Owner EPS | N/A | N/A | N/A |
| Book Value | N/A | N/A | 0.00 |
| Cash Flow/Share | N/A | N/A | 0.00 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | N/A | N/A | 0.0M |
| Valuation | |||
| P/E Ratio | 0.0 | 0.0 | 0.0 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | 3.7 | 3.7 | N/A |
| Price/Book | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 |
| Avg. Price | 0.62 | 0.91 | 1.42 |
| Year-End Price | 0.88 | 0.80 | 1.42 |
LAVIPHARM S.A. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 6.4% with a gross margin of 46.8%.
LAVIPHARM S.A. (LAVI-AT) has a 5-year average return on invested capital (ROIC) of 6.4%. This is below average and may indicate limited pricing power.
LAVIPHARM S.A. (LAVI-AT) does not currently pay a regular dividend.
LAVIPHARM S.A. (LAVI-AT) operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
LAVIPHARM S.A. (LAVI-AT) reported annual revenue of $57 million in its most recent fiscal year, based on SEC EDGAR filings.
LAVIPHARM S.A. (LAVI-AT) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LAVIPHARM S.A. (LAVI-AT) has a debt-to-equity ratio of 0.39. This indicates a conservatively financed balance sheet.
LAVIPHARM S.A. (LAVI-AT) reported earnings per share (EPS) of $555.34 in its most recent fiscal year.
LAVIPHARM S.A. (LAVI-AT) has a 5-year average gross margin of 46.8%. This indicates decent pricing power.
The Ledger Terminal provides 2 years of financial data for LAVIPHARM S.A. (LAVI-AT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.